Skip to main content
Clinical Trials/NCT01937754
NCT01937754UnknownPhase 1

Study of the Effects of an Oral Nitric Oxide Supplement on Functional Capacity and Blood Pressure in Healthy Adults With Prehypertension

Neogenis Laboratories2 sites in 1 country30 target enrollmentStarted: January 1, 2013Last updated:
Conditions

Trial Snapshot

Phase
Phase 1
Sponsor
Enrollment
30
Locations
2
Primary Endpoint
Reduction in Systolic and Diastolic Blood Pressure Readings

Study Overview

Brief Summary

Oral supplementation of Neo40(TM), a nitrate lozenge, will reduce blood pressure in healthy adults with clinical prehypertension.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Supportive Care
Masking
Double (Participant, Investigator)

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults between the ages of 18 to 80 years
  • Two blood pressure readings of >/=135/80 mmHg at rest, thus representing prehypertension
  • Informed consent

Exclusion Criteria

  • Existence of any significant internal or cardiovascular disease;
  • Current use of any antihypertensive medication.
  • Inability to give informed consent, or fill out standard questionnaires or inability to follow up clinically.

Outcomes

Primary Outcomes

Reduction in Systolic and Diastolic Blood Pressure Readings

Time Frame: 30 days

Two blood pressure readings at rest will be taken at baseline and again after thirty days during the follow-up appointment.

Secondary Outcomes

  • Improvement in Functional Capacity(30 days)

Investigators

Sponsor
Neogenis Laboratories
Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Ernst Schwarz

Attending Cardiologist, Professor of Medicine

Neogenis Laboratories

Study Sites (2)

Loading locations...

Similar Trials